Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. We discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). We are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. Our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines.
Company Growth (employees)
Cambridge, US
Size (employees)
674 (est)+43%
Ironwood Pharmaceuticals is headquartered in Cambridge, US

Key People at Ironwood Pharmaceuticals

Peter M. Hecht

Peter M. Hecht

Brian M. Cali

Brian M. Cali

Co-Founder and Vice President of Program Management
Gina Bornino Miller

Gina Bornino Miller

Co-Founder and Director
George Conrades

George Conrades


Ironwood Pharmaceuticals Office Locations

Ironwood Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
301 Binney St

Ironwood Pharmaceuticals Metrics

Ironwood Pharmaceuticals Financial Metrics

Revenue (2016)

$274 m

Revenue growth (2015-16), %


Net income (2016)

($81.7 m)

Market capitalization (21-Mar-2017)

$2.5 b

Closing share price (21-Mar-2017)


Cash (31-Dec-2016)

$54 m
Ironwood Pharmaceuticals's current market capitalization is $2.5 b.
Ironwood Pharmaceuticals's revenue was reported to be $274 m in FY, 2016 which is a 83.2% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$22.9 m$76.4 m$149.6 m$274 m

Revenue growth, %


Gross profit

$15.7 m$50.9 m$149.5 m

Gross profit Margin, %


Operating expense total

$267.7 m$220.2 m$251.6 m


($252 m)($169.4 m)($102.1 m)

EBIT margin, %


Net Income

($272.8 m)($189.6 m)($142.7 m)($81.7 m)
FY, 2013FY, 2014FY, 2015FY, 2016


$75.5 m$74.3 m$261.3 m$54 m

Accounts Receivable

$513 k$10 k$2.9 m$933 k


$6.2 m$10.6 m$6.3 m$9 m

Current Assets

$229.1 m$289.7 m$500.2 m$380.2 m


$37.4 m$29.8 m$21.1 m$20.5 m


$785 k

Total Assets

$279 m$333.5 m$619.1 m$709.8 m

Accounts Payable

$10.1 m$9.8 m$8.6 m$17.7 m

Total Debt

$175.8 m

Current Liabilities

$41 m$60.5 m$76.5 m$91.1 m

Common Stock

$103 k$125 k$127 k$133 k

Additional Paid-in Capital

$815.9 m$1.1 b$1.2 b$1.3 b

Retained Earnings

($777.8 m)($967.4 m)($1.1 b)($1.2 b)

Total Equity

$38.2 m$88.6 m$95.1 m$66.7 m

Debt to Equity Ratio

4.6 x

Debt to Assets Ratio

0.6 x

Financial Leverage

7.3 x3.8 x6.5 x10.6 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($272.8 m)($189.6 m)($142.7 m)($81.7 m)

Depreciation and Amortization

$11.7 m$12.3 m$11.6 m$10.3 m

Accounts Receivable

($1.7 m)($24 m)($29 m)($10 m)


($52 k)($3.9 m)$2.6 m($3.1 m)

Accounts Payable

($11.7 m)$1.4 m

Cash From Operating Activities

($273.4 m)($155.6 m)($106.9 m)($25.4 m)

Purchases of PP&E

($9.6 m)($3.5 m)($4 m)($4.2 m)

Cash From Investing Activities

($101.4 m)($56.6 m)

Cash From Financing Activities

$313.6 m$210.9 m$303.1 m($4.2 m)

Interest Paid

$18.4 m$19.6 m$22.7 m$24.5 m

Ironwood Pharmaceuticals Market Value History

Ironwood Pharmaceuticals Median Salaries

Source: 16 public H-1B filings from Ironwood Pharmaceuticals

Ironwood Pharmaceuticals Online Presence

Ironwood Pharmaceuticals Company Life

You may also be interested in